Sotera Health Co Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.2B+10.5% YoYTTM through 30 Jun 2026
Net Income $163.5M+268.2% YoYTTM through 30 Jun 2026
Free Cash Flow $112.7MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 55.5% |
| EBITDA Margin | 29.5% |
| Operating Margin | 26.0% |
| Net Margin | 13.4% |
Returns
12.9%ROE
2.4%ROA
6.7%ROIC
Balance Sheet Health
Debt / Equity3.51x
Current Ratio2.46x
Net Debt$1.8B
Cash & Equivalents$356.7M
Quality Metrics
Altman Z-Score1.80
Piotroski F-Score7 / 9
FCF Margin9.3%
Rule of 4011.8
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $1.2B
Diluted EPS$0.57TTMFY2025: $0.27
Dividend
No dividend
Capital Allocation
Capex Intensity14.8%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Sterigenics | $756M | +8.3% | View detailsExpected to maintain steady growth driven by outsourced terminal sterilization demand. |
| Nordion | $188M | +8.2% | View detailsPerformance heavily tied to the timing of cobalt-60 harvest schedules. |
| Nelson Labs | $220M | -3.9% | View detailsFocusing on lab optimization and core testing services to offset expert advisory declines. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.